Welcome to Your AVEO Orientation
2012
CONFIDENTIAL
1
Orientation Schedule – Day 1
Time Topic Facilitator
9:00 AM Breakfast and AVEO Overview Senior Management
9:45 AM AVEO Day-to-Day Resources Tracey Janesheski, HR Associate
10:00 AM Keeping the Workplace Safe Safety
10:15 AM Your AVEO Benefits & EE Photo Jaimie Mailander, HR Associate
12:00 PM Lunch Hiring Manager
2nd Day
9:30 AMQuality Assurance Orientation
Within 1st 60 DaysCheck-In with Your HR Business Partner
Within 1st 60 Days Legal Orientation Joe Vittiglio, Senior VP & General Counsel
27/17/2013 2 CONFIDENTIAL
Who We Are
37/17/2013 3 CONFIDENTIAL
4
The AVEO Executive Committee
From top left corner: Tuan Ha-Ngoc, Jeno Gyuris, Murray Robinson, David Johnston.
Seated, from left: Elan Ezickson, Michael Bailey, Nell Jones, Joseph Vittiglio, Bill Slichenmyer
7/17/2013 4 CONFIDENTIAL
Tuan Ha-NgocPresident/CEO
Joseph VittiglioSr. VP & General
Counsel
-Intellectual Property
Nell JonesSr. VP, Human
Resources
Elan EzicksonExecutive VP &
COO
-Medical Affairs-Technical Operations-Program & Alliance
Management
Michael BaileyChief Commercial
Officer
Commercial & Marketing
Jeno GyurisCSO
-Translational Research-Preclinical
Development-Bioinformatics
David JohnstonCFO
-Finance-Investor Relations
-Facilities-IT
Bill SlichenmyerCMO
-Clinical-Pharmacovigilance
-Biometrics-Regulatory Affairs
Carole Varanelli VP Quality
Rob KloppenbergVP, Corp. Comm. & Public Affairs
The AVEO Organization
CLINICAL ACTIVITIES AND PIPELINE DEALS
HRP AND HRP DEALS
MERGER OF HRP & PRODUCTS/CLINICAL PROGRAMS
SERIES A SERIES B SERIES C SERIES D SUCCESSFUL IPO PIPE FOLLOW-ON
TIVOZANIB PH 2 RCC STUDY INITIATED
FICLATUZUMAB PH 1 INITIATED
AVEO REGAINSRIGHTS TO
FICLATUZUMAB
TIVO-1INITIATED FICLATUZUMAB
PH 2 NSCLC INITIATED
BATON-RCC
BATON-CRC
2002-2012: A Decade of Delivery
2002 | | | | | 2012 6
Human Response Platform™: Insights into Cancer Biology
7/17/2013 CONFIDENTIAL7
U.S. Patent No. 6,639,121 Issued in 2003
Discovery and
validation of
functionally relevant
targets
Maturing pipeline of
novel functional
antibodies
Biomarker-driven identification of responsive patient populations
Genetic signatures of tumors informs rational choice of drug combinations
Biomarker data provides
opportunity to optimize
benefits in selected patients
Supports pricing and
reimbursement
Building A Sustainable Pipeline
7/17/2013 CONFIDENTIAL8
= FOUNDATION FOR BIOMARKER CLINICAL STATEGIES
*Aveo and Astellas Pharma Inc. have a worldwide agreement to co-develop and commercialize tivozanib outside of Asia
**Anti-ErbB3 program is strategically partnered with Biogen Idec
7/17/2013 CONFIDENTIAL9
TIVOZANIB
Potent, Selective and
Long Half-Life Inhibitor
of All Three VEGF
Receptors
RCC market valued at $2B WW1
Despite advances, unmet medical need persists2
Tivozanib: Potential Standard of Care in First-Line RCC
• Current therapies provide less than
12 months of first-line PFS and
therefore there remains a significant
unmet need2
• Reducing the dosage or delaying
treatment of therapies due to AEs
(fatigue, diarrhea and hand-foot
syndrome) is a major limitation2
• Many patients cannot tolerate
current therapies for a long period of
time, impacting potential to achieve
maximal efficacy2
7/17/2013 CONFIDENTIAL101. Wolters Kluwer and IMS Health
2. Campbell Alliance interviews with 7 KOLs. Aug, 8 through Aug. 12, 2011.
Improved EfficacyImproved Safety
and Tolerability
7/17/2013 CONFIDENTIAL
TIVO-1 Top-Line: Statistically Significant Superiority
• Well-tolerated safety profile consistent with Phase 2– Hypertension was most common side effect; on-target class effect and
manageable
– Phase 2 experience:
• Low rate of dose reductions and interruptions, and serious side effects (grade 3/4)
• Hypertension and dysphonia most commonly reported side effects; both mechanism-related, manageable and reversible
• Side effects commonly associated with other VEGFR inhibitors (diarrhea, fatigue and hand-foot syndrome) were notably low
11
SAFETY
EFFICACY
Median PFS / Treatment Naïve (70% of overall)
Tivozanib 12.7 months
Sorafenib 9.1 months
Median PFS / Overall Study
Tivozanib 11.9 months
Sorafenib 9.1 months
Our Total Approach to Patient
7/17/2013 CONFIDENTIAL12
AccessDisease Management
AdvocacySupport
Predictive
Biomarkers
Efficacy Tolerability
Partnership with Astellas
• In February 2011, AVEO and Astellas entered into a worldwide
agreement outside of Asia to develop and commercialize tivozanib
for the treatment of a broad range of cancers.
Astellas, located in Tokyo, Japan, is a pharmaceutical company
with approximately 16,800 employees worldwide
• AVEO will be responsible for the manufacturing of tivozanib and
lead commercialization in North America
• Astellas will lead commercialization in the European Union
• AVEO and Astellas plan to jointly conduct and fund the expansion
of tivozanib clinical development into additional solid tumor types.
CONFIDENTIAL137/17/2013
Where We are Today
• 220+ employees
• US and EU field presence (Germany, UK, France)
14
Cambridge, MA
7/17/2013 14 CONFIDENTIAL
Windsor, UK
AVEO Clinical Trial Sites and MSL Locations
CONFIDENTIAL157/17/2013
RCC KOL Location
CCC Location
Current MSL
Location
16
Future AVEO Headquarters:650 East Kendall
7/17/2013 16
Your AVEO Day-to-Day Resources
7/17/2013 CONFIDENTIAL17
New Hire Resources on the AVEO Insider
18http://aveo/metadot/index.pl?id=3139&isa=Category&op=show7/17/2013 18 CONFIDENTIAL
7/17/2013 CONFIDENTIAL19
AVEO Policies
• AVEO employees are required to read and acknowledge receipt
of the following Company policies– Non-Discrimination & Non-Harassment
– Time Away From Work
– Electronic Communications & Info Systems
– Family & Medical Leave Act
– Laboratory Notebook Policy
– Insider Trading
– Disclosure Policy
– Written Comprehensive Information Security Program (WISP)
• May be required if as part of your position you have access to certain sensitive information
– Overtime and Holiday Policy
• Required only if you are an hourly, or non-exempt, employee
JULY 17, 2013 CONFIDENTIAL19
Staying Informed, Getting Involved
• Quarterly All-Company Meetings
• Annual Summer Outing
• Annual Post-Holiday Celebration
• Various charitable events
20©2012 Vertex Pharmaceuticals Incorporated7/17/2013 20 CONFIDENTIAL
2012 Summer Events : 10th Anniversary Year
7/17/2013 CONFIDENTIAL21
• Celebration at Fenway Park
• Guided tour, dinner, AVEO apparel
• Prouty Ride to benefit the Norris Cotton
Cancer Center
• Second Quarter all company meeting &
poster session
• Day of Community Service
• Corporate Donation of $10,000 in the
name of all employees to the Jimmy
FundJULY 17, 2013 CONFIDENTIAL21
The AVEO Way: Putting the Patient First
7/17/2013 22 CONFIDENTIAL
AVEO Oncology is…
…passionate in our pursuit of improving the lives of cancer patients…
…powered by innovation…
…supportive of a creative and collaborative culture…
…committed to creating value for our shareholders.
This is the AVEO Way – the Human Response.
AVEO Rewards and Recognition Program
• Annual CEO Award - $5,000
• Executive Team Award - $500
• Team Award - $150 AmEx Gift Card
• Spot Award (Individual) - $150 AmEx Gift Card
• Thanks Award - $25 AmEx Gift Card
AVEO’s CEO AwardRecipients:2012 – Andrew Strahs, Sr. Director, Biometrics
7/17/2013 23 CONFIDENTIAL
Connect with Your AVEO Ambassador
• Ambassadors are employees at all levels who:– Know the culture – Know how to get things done – Convey practical knowledge
• Your Ambassador will help you navigate our campus and culture for the first 30 days
247/17/2013 24 CONFIDENTIAL
AVEO Employee Referral Program
257/17/2013 25 CONFIDENTIAL
26
Current AVEO Campus Map
7/17/2013 26 CONFIDENTIAL
27
Future AVEO Headquarters:650 East Kendall
7/17/2013 27